Juan W Valle

List of Publications by Year
in descending order

253 papers	30,364 citations	15360 64 h-index	5131 164 g-index
330 all docs	330 docs citations	330 times ranked	25609 citing authors

#	Article	IF	Citations
1	Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. New England Journal of Medicine, 2010, 362, 1273-1281.	29.7	3,522
2	Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors. New England Journal of Medicine, 2011, 364, 501-513.	29.7	2,255
3	Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet, The, 2017, 389, 1011-1024.	12.1	1,542
4	Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 557-588.	18.0	1,321
5	Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection. JAMA - Journal of the American Medical Association, 2010, 304, 1073.	7.0	1,225
6	Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet, The, 2016, 387, 968-977.	12.1	1,002
7	Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncology, The, 2019, 20, 663-673.	10.7	839
8	Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer. Journal of Clinical Oncology, 2009, 27, 5513-5518.	5.4	715
9	Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncology, The, 2020, 21, 796-807.	10.7	690
10	Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2016, 27, v28-v37.	1.3	545
11	Biliary tract cancer. Lancet, The, 2021, 397, 428-444.	12.1	522
12	Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma. JAMA - Journal of the American Medical Association, 2012, 308, 147.	7.0	516
13	Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial. Lancet Oncology, The, 2021, 22, 690-701.	10.7	446
14	New Horizons for Precision Medicine in Biliary Tract Cancers. Cancer Discovery, 2017, 7, 943-962.	14.1	438
15	Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncology, The, 2014, 15, 601-611.	10.7	376
16	Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evidence, 2022, 1, .	10.0	367
17	Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study. Journal of Clinical Oncology, 2014, 32, 504-512.	5.4	364
18	Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials. Annals of Oncology, 2014, 25, 391-398.	1.3	329

#	Article	IF	Citations
19	Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline. Journal of Clinical Oncology, 2019, 37, 1015-1027.	5.4	325
20	Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2014, 15, 829-840.	10.7	306
21	The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. Cancer Immunology, Immunotherapy, 2017, 66, 1425-1436.	4.4	290
22	Second-line chemotherapy in advanced biliary cancer: a systematic review. Annals of Oncology, 2014, 25, 2328-2338.	1.3	287
23	A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Investigational New Drugs, 2011, 29, 1029-1037.	2.7	272
24	Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome. Journal of Clinical Oncology, 2017, 35, 14-23.	5.4	269
25	Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation. JAMA Oncology, 2021, 7, 1669.	7.3	247
26	Molecular targeted therapies: Ready for â€œprime timeâ€•in biliary tractÂcancer. Journal of Hepatology, 2020, 73, 170-185.	3.9	246
27	Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study â€“ The UK ABC-01 Study. British Journal of Cancer, 2009, 101, 621-627.	6.5	245
28	Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial. Journal of the National Cancer Institute, 2014, 106, djt347.	6.3	237
29	A pilot study to explore circulating tumour cells in pancreatic cancer as a novel biomarker. British Journal of Cancer, 2012, 106, 508-516.	6.5	236
30	Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial. Lancet Oncology, The, 2015, 16, 967-978.	10.7	228
31	A Systematic Review of the Burden of Pancreatic Cancer in Europe: Real-World Impact on Survival, Quality of Life and Costs. Journal of Gastrointestinal Cancer, 2015, 46, 201-211.	1.4	205
32	The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 2019, 269, 520-529.	4.4	199
33	Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity. Cancer Cell, 2021, 39, 1227-1244.e20.	16.6	194
34	Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma. JAMA Surgery, 2019, 154, 1038.	4.5	179
35	Blockade of Platelet-Derived Growth Factor Receptor-Beta by CDP860, a Humanized, PEGylated di-Fab', Leads to Fluid Accumulation and Is Associated With Increased Tumor Vascularized Volume. Journal of Clinical Oncology, 2005, 23, 973-981.	5.4	168
36	Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2020, 21, 398-411.	10.7	161

#	Article	IF	Citations
37	Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. Journal of Hepatology, 2022, 76, 1109-1121.	3.9	153
38	Randomized, Placebo-Controlled, Phase III Study of Oxaliplatin, Fluorouracil, and Leucovorin With or Without PTK787/ZK 222584 in Patients With Previously Treated Metastatic Colorectal Adenocarcinoma. Journal of Clinical Oncology, 2011, 29, 2004-2010.	5.4	151
39	Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. Annals of Oncology, 2017, 28, 339-343.	1.3	151
40	HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?. Cancer and Metastasis Reviews, 2017, 36, 141-157.	6.2	131
41	FIGHT-302: first-line pemigatinib vs gemcitabine plus cisplatin for advanced cholangiocarcinoma with FGFR2 rearrangements. Future Oncology, 2020, 16, 2385-2399.	2.4	108
42	Telotristat Etiprate for Carcinoid Syndrome: A Single-Arm, Multicenter Trial. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 1511-1519.	3.6	99
43	Effectiveness of Progressive Resistive Exercise (PRE) in the context of HIV: systematic review and meta-analysis using the Cochrane Collaboration protocol. BMC Infectious Diseases, 2017, 17, 268.	3.0	92
44	Prognostic factors for progression-free and overall survival in advanced biliary tract cancer. Annals of Oncology, 2016, 27, 134-140.	1.3	88
45	18F-fluorodeoxyglucose positron emission tomography (18FDG-PET) for patients with biliary tract cancer: Systematic review and meta-analysis. Journal of Hepatology, 2019, 71, 115-129.	3.9	86
46	Biliary tract cancers: current knowledge, clinical candidates and future challenges . Cancer Management and Research, 2019, Volume 11, 2623-2642.	2.0	85
47	A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial. Annals of Oncology, 2017, 28, 1309-1315.	1.3	84
48	Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study. Journal of Clinical Oncology, 2022, 40, 2048-2057.	5.4	84
49	The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patients with advanced pancreatic cancer. Cancer Immunology, Immunotherapy, 2014, 63, 175-183.	4.4	81
50	Current standards and future perspectives in adjuvant treatment for biliary tract cancers. Cancer Treatment Reviews, 2020, 84, 101936.	8.0	79
51	Advances in the treatment of metastatic or unresectable biliary tract cancer. Annals of Oncology, 2010, 21, vii345-vii348.	1.3	77
52	Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 1411-1422.	10.7	76
53	Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinomaâ€”a meta-analysis. European Journal of Cancer, 2018, 105, 1-9.	2.9	73
54	Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers. Journal of Clinical Medicine, 2020, 9, 2854.	2.5	73

#	Article	IF	Citations
55	Medical treatment for cholangiocarcinoma. Liver International, 2019, 39, 123-142.	3.9	72
56	Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites. Journal of Hepatology, 2020, 73, 1404-1414.	3.9	72
57	Impact of high tumor mutational burden in solid tumors and challenges for biomarker application. Cancer Treatment Reviews, 2020, 89, 102084.	8.0	67
58	Serum and plasma 5-hydroxyindoleacetic acid as an alternative to 24-h urine 5-hydroxyindoleacetic acid measurement. Annals of Clinical Biochemistry, 2016, 53, 554-560.	1.6	64
59	A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study. BMC Cancer, 2016, 16, 153.	2.6	64
60	Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. Lancet Oncology, The, 2017, 18, 486-499.	10.7	62
61	Biliary Tract Cancer: State of the Art and potential role of DNA Damage Repair. Cancer Treatment Reviews, 2018, 70, 168-177.	8.0	59
62	Circulating biomarkers in hepatocellular carcinoma. Cancer Chemotherapy and Pharmacology, 2014, 74, 323-332.	2.4	58
63	Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis. Cancer Treatment Reviews, 2021, 99, 102258.	8.0	58
64	Capecitabine and streptozocinÂ±cisplatin in advanced gastroenteropancreatic neuroendocrine tumours. European Journal of Cancer, 2014, 50, 902-911.	2.9	57
65	Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509). Journal of Clinical Oncology, 2021, 39, 2304-2312.	5.4	57
66	Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma. Journal of Hepatology, 2023, 79, 93-108.	3.9	57
67	Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study. Journal of Clinical Oncology, 2019, 37, 2571-2580.	5.4	54
68	The Association of a Panel of Biomarkers with the Presence and Severity of Carcinoid Heart Disease: A Cross-Sectional Study. PLoS ONE, 2013, 8, e73679.	2.5	53
69	Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Analysis. Journal of Vascular and Interventional Radiology, 2020, 31, 1035-1043.e2.	0.5	52
70	Impact of neuroendocrine morphology on cancer outcomes and stage at diagnosis: a UK nationwide cohort study 2013â€“2015. British Journal of Cancer, 2019, 121, 966-972.	6.5	50
71	Randomized phase II study of cyclophosphamide, doxorubicin, and vincristine compared with single-agent carboplatin in patients with poor prognosis small cell lung carcinoma. Cancer, 2001, 92, 601-608.	4.1	49
72	Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer. Nature Communications, 2018, 9, 4672.	13.0	49

#	Article	IF	Citations
73	Heterocellular OSM-OSMR signalling reprograms fibroblasts to promote pancreatic cancer growth and metastasis. Nature Communications, 2021, 12, 7336.	13.0	49
74	A systematic review of non-surgical treatments for pancreatic neuroendocrine tumours. Cancer Treatment Reviews, 2014, 40, 376-389.	8.0	46
75	Chemotherapy for advanced non-pancreatic well-differentiated neuroendocrine tumours of the gastrointestinal tract, a systematic review and meta-analysis: A lost cause?. Cancer Treatment Reviews, 2016, 44, 26-41.	8.0	46
76	Outcome of second-line chemotherapy for biliary tract cancer. European Journal of Cancer, 2013, 49, 1511.	2.9	45
77	Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial. Targeted Oncology, 2016, 11, 815-824.	3.7	45
78	Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study. Digestive and Liver Disease, 2016, 48, 552-558.	0.9	45
79	Liver Metastases of Intrahepatic Cholangiocarcinoma: Implications for an Updated Staging System. Hepatology, 2021, 73, 2311-2325.	8.1	45
80	Methods for Adjusting for Bias Due to Crossover in Oncology Trials. Pharmacoeconomics, 2014, 32, 533-546.	3.6	43
81	Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2015, 14, 115-122.e2.	2.4	43
82	Serial surveillance of carcinoid heart disease: factors associated with echocardiographic progression and mortality. British Journal of Cancer, 2014, 111, 1703-1709.	6.5	42
83	Current and novel therapeutic opportunities for systemic therapy in biliary cancer. British Journal of Cancer, 2020, 123, 1047-1059.	6.5	42
84	Quality of life, long-term survivors and long-term outcome from the ABC-02 study. British Journal of Cancer, 2016, 114, 965-971.	6.5	41
85	Somatostatin analogue-induced pancreatic exocrine insufficiency in patients with neuroendocrine tumors: results of a prospective observational study. Expert Review of Gastroenterology and Hepatology, 2018, 12, 723-731.	3.0	41
86	Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer. Scientific Reports, 2019, 9, 11610.	3.4	39
87	Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 study. Lancet Oncology, The, 2021, 22, 1468-1482.	10.7	36
88	A comparison of diagnostic imaging modalities for colorectal liver metastases. European Journal of Surgical Oncology, 2014, 40, 545-550.	1.0	35
89	Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe. Pancreatology, 2019, 19, 97-104.	1.8	35
90	UGT1A1*28 Genotype Predicts Gastrointestinal Toxicity in Patients Treated With Intermediate-Dose Irinotecan. Pharmacogenomics, 2009, 10, 733-739.	1.4	34

#	Article	IF	Citations
91	Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer. Critical Reviews in Oncology/Hematology, 2011, 80, 31-39.	4.5	34
92	Practical management of sunitinib toxicities in the treatment of pancreatic neuroendocrine tumors. Cancer Treatment Reviews, 2014, 40, 1230-1238.	8.0	34
93	TG01/GM-CSF and adjuvant gemcitabine in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-01): a single-arm, phase 1/2 trial. British Journal of Cancer, 2020, 122, 971-977.	6.5	34
94	Design and Validation of the GI-NEC Score to Prognosticate Overall Survival in Patients With High-Grade Gastrointestinal Neuroendocrine Carcinomas. Journal of the National Cancer Institute, 2017, 109, djw277.	6.3	33
95	Evaluation of diagnostic and prognostic significance of Ki-67 index in pulmonary carcinoid tumours. Clinical and Translational Oncology, 2017, 19, 579-586.	2.5	33
96	The role of adjuvant chemotherapy andÂradiotherapy for cholangiocarcinoma. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2015, 29, 333-343.	2.4	32
97	PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours. Oncotarget, 2018, 9, 14922-14938.	1.9	32
98	A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer. European Journal of Cancer, 2010, 46, 526-533.	2.9	30
99	Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. British Journal of Cancer, 2018, 118, 947-954.	6.5	30
100	Telotristat ethyl: a new option for the management of carcinoid syndrome. Expert Opinion on Pharmacotherapy, 2016, 17, 2487-2498.	1.9	29
101	New molecular and immunotherapeutic approaches in biliary cancer. ESMO Open, 2017, 2, e000152.	4.3	28
102	Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer. Journal of Hepatology, 2020, 73, 1109-1117.	3.9	28
103	Evaluation of Hypertension and Proteinuria as Markers of Efficacy in Antiangiogenic Therapy for Metastatic Colorectal Cancer. Journal of Clinical Gastroenterology, 2014, 48, 430-434.	2.3	26
104	Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder. British Journal of Cancer, 2016, 115, 1032-1038.	6.5	26
105	Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy. Cancers, 2018, 10, 17.	3.8	26
106	Chemotherapy for advanced gallbladder cancer (GBC): A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2021, 163, 103328.	4.5	26
107	Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease. European Journal of Cancer, 2015, 51, 1694-1703.	2.9	25
108	Pancreatic cancer: Are "liquid biopsies" ready for prime-time?. World Journal of Gastroenterology, 2016, 22, 7175.	3.4	25

#	Article	IF	Citations
109	A study of appendiceal crypt cell adenocarcinoma (so-called goblet cell carcinoid and its related) Tj ETQq1 1 0.784314 rgBT /Overlock 1	2.3	25
110	Treatment of inoperable hepatocellular carcinoma with pegylated liposomal doxorubicin (PLD): results of a phase II study. British Journal of Cancer, 2005, 92, 628-630.	6.5	24
111	Next-Generation Biomarkers for Cholangiocarcinoma. Cancers, 2021, 13, 3222.	3.8	24
112	Lack of genetic evidence that fatty liver disease predisposesÂtoÂCOVID-19. Journal of Hepatology, 2020, 73, 709-711.	3.9	24
113	Impact of biliary stent-related events in patients diagnosed with advanced pancreatobiliary tumours receiving palliative chemotherapy. World Journal of Gastroenterology, 2016, 22, 6065.	3.4	24
114	Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response. British Journal of Cancer, 2018, 118, 181-188.	6.5	23
115	Potential influence of the microbiome environment in patients with biliary tract cancer and implications for therapy. British Journal of Cancer, 2022, 126, 693-705.	6.5	23
116	Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 2017, 18, 909.	4.2	22
117	Clinical and Translational Research Challenges in Biliary Tract Cancers. Current Medicinal Chemistry, 2020, 27, 4756-4777.	2.4	22
118	Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine Carcinoma. Clinical Cancer Research, 2022, 28, 1999-2019.	7.2	22
119	Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. British Journal of Cancer, 2020, 123, 709-713.	6.5	21
120	Comparison of biochemical, microbial and mucosal mRNA expression in bile acid diarrhoea and irritable bowel syndrome with diarrhoea. Gut, 2023, 72, 54-65.	13.5	21
121	Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer. European Journal of Cancer, 2015, 51, 1381-1388.	2.9	20
122	Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome. Clinical Therapeutics, 2018, 40, 952-962.e2.	2.3	20
123	Circulating biomarkers during treatment in patients with advanced biliary tract cancer receiving cediranib in the UK ABC-03 trial. British Journal of Cancer, 2018, 119, 27-35.	6.5	19
124	The Impact of 68Gallium DOTA PET/CT in Managing Patients With Sporadic and Familial Pancreatic Neuroendocrine Tumours. Frontiers in Endocrinology, 2021, 12, 654975.	3.5	19
125	Variation in Cardiac Screening and Management of Carcinoid Heart Disease in the UK and Republic of Ireland. Clinical Oncology, 2015, 27, 741-746.	1.4	18
126	Update on Treatment Options for Advanced Bile Duct Tumours: Radioembolisation for Advanced Cholangiocarcinoma. Current Oncology Reports, 2017, 19, 50.	4.1	18

#	Article	IF	Citations
127	A phase I and pharmacokinetic study of OSI-7904L, a liposomal thymidylate synthase inhibitor in combination with oxaliplatin in patients with advanced colorectal cancer. Cancer Chemotherapy and Pharmacology, 2008, 61, 579-585.	2.4	17
128	Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. Journal of Gastrointestinal Oncology, 2016, 7, 819-827.	1.4	17
129	Sunitinib In Patients With Pancreatic Neuroendocrine Tumors: Update of Safety Data. Future Oncology, 2019, 15, 1219-1230.	2.4	17
130	Impact on prognosis of early weight loss during palliative chemotherapy in patients diagnosed with advanced pancreatic cancer. Pancreatology, 2020, 20, 1682-1688.	1.8	17
131	A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08). Oncologist, 2021, 26, e669-e678.	4.1	17
132	Systemic therapy of gallbladder cancer: review of first line, maintenance, neoadjuvant and second line therapy specific to gallbladder cancer. Chinese Clinical Oncology, 2019, 8, 43-43.	1.3	17
133	Phase II Trial of Cetuximab and Conformal Radiotherapy Only in Locally Advanced Pancreatic Cancer with Concurrent Tissue Sampling Feasibility Study. Translational Oncology, 2014, 7, 55-64.	3.8	16
134	NUC-1031/cisplatin versus gemcitabine/cisplatin in untreated locally advanced/metastatic biliary tract cancer (NuTide:121). Future Oncology, 2020, 16, 1069-1081.	2.4	16
135	The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers. PLoS ONE, 2018, 13, e0206007.	2.5	15
136	Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs). Cancers, 2020, 12, 1988.	3.8	15
137	Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial. Journal of Cancer Research and Clinical Oncology, 2022, 148, 475-485.	2.6	15
138	Evaluation and management of incidental gallbladder cancer. Chinese Clinical Oncology, 2019, 8, 37-37.	1.3	15
139	Intrahepatic cholangiocarcinoma hidden within cancer of unknown primary. British Journal of Cancer, 2022, 127, 531-540.	6.5	15
140	Criteria for preclinical models of cholangiocarcinoma: scientific and medical relevance. Nature Reviews Gastroenterology and Hepatology, 2023, 20, 462-480.	18.0	15
141	Immunobiology of cholangiocarcinoma. Journal of Hepatology, 2023, 79, 867-875.	3.9	15
142	Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma. British Journal of Cancer, 2020, 122, 1760-1768.	6.5	14
143	Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions. Gut, 2022, , gutjnl-2022-327099.	13.5	14
144	Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors. Cancer Chemotherapy and Pharmacology, 2015, 75, 1099-1114.	2.4	13

#	Article	IF	Citations
145	Prognostic factors for disease relapse in patients with neuroendocrine tumours who underwent curative surgery. Surgical Oncology, 2016, 25, 223-228.	1.8	13
146	Leukocytosis and alteration of hemoglobin level in patients with severe <scp>COVID</scp>â€19: Association of leukocytosis with mortality. Health Science Reports, 2020, 3, e194.	1.5	13
147	The assessment of pancreatic exocrine function in patients with inoperable pancreatic cancer: In need of a new gold-standard. Pancreatology, 2020, 20, 668-675.	1.8	13
148	NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC). BMJ Open, 2020, 10, e034527.	2.1	13
149	Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era. European Journal of Cancer, 2021, 144, 200-214.	2.9	13
150	Setup of multidisciplinary team discussions for patients with cholangiocarcinoma: current practice and recommendations from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). ESMO Open, 2022, 7, 100377.	4.3	13
151	A Phase II Study of Weekly Cisplatin and Gemcitabine in Patients With Advanced Pancreatic Cancer: Is This a Strategy Still Worth Pursuing?. Pancreas, 2006, 32, 51-57.	1.1	12
152	Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a Phase I study. British Journal of Cancer, 2007, 96, 38-43.	6.5	12
153	Follow-Up Recommendations after Curative Resection of Well-Differentiated Neuroendocrine Tumours: Review of Current Evidence and Clinical Practice. Journal of Clinical Medicine, 2019, 8, 1630.	2.5	12
154	The clinical and cost-effectiveness of supplemental parenteral nutrition in oncology. ESMO Open, 2020, 5, e000709.	4.3	12
155	Clinical benefit of surveillance after resection of pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. European Journal of Surgical Oncology, 2021, 47, 2248-2255.	1.0	12
156	18F-FLT PET imaging of cellular proliferation in pancreatic cancer. Critical Reviews in Oncology/Hematology, 2016, 99, 158-169.	4.5	11
157	Irreversible Electroporation in pancreatic ductal adenocarcinoma: IsÂthere a role in conjunction with conventional treatment?. European Journal of Surgical Oncology, 2018, 44, 1486-1493.	1.0	11
158	Adjuvant chemotherapy and outcomes in patients with nodal and resection marginâ€negative pancreatic ductal adenocarcinoma: A systematic review and metaâ€analysis. Journal of Surgical Oncology, 2019, 119, 932-940.	1.7	11
159	NUC-1031, use of ProTide technology to circumvent gemcitabine resistance: current status in clinical trials. Medical Oncology, 2020, 37, 61.	2.7	11
160	Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinoma. British Journal of Cancer, 2006, 95, 450-456.	6.5	10
161	Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study. British Journal of Cancer, 2016, 115, 420-424.	6.5	10
162	Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. British Journal of Cancer, 2018, 118, 1084-1088.	6.5	10

#	Article	IF	Citations
163	Urgent need for consensus: international survey of clinical practice exploring use of platinum-etoposide chemotherapy for advanced extra-pulmonary high grade neuroendocrine carcinoma (EP-G3-NEC). Clinical and Translational Oncology, 2019, 21, 950-953.	2.5	10
164	Prevalence of symptomatic pancreatic exocrine insufficiency in patients with pancreatic malignancy: nutritional intervention may improve survival. Cancer Research Frontiers, 2016, 2, 352-367.	0.2	10
165	Faecal occult blood loss accurately predicts future detection of colorectal cancer. A prognostic model. Gut, 2023, 72, 101-108.	13.5	10
166	Impact of laparotomy and liver resection on the peritoneal concentrations of fibroblast growth factor 2, vascular endothelial growth factor and hepatocyte growth factor. Journal of Cancer Research and Clinical Oncology, 2006, 132, 41-44.	2.6	9
167	Understanding chemotherapy treatment pathways of advanced colorectal cancer patients to inform an economic evaluation in the United Kingdom. British Journal of Cancer, 2010, 103, 315-323.	6.5	9
168	Why hasn't the National Institute been â€˜NICEâ€™ to patients with colorectal cancer?. British Journal of Cancer, 2002, 86, 1667-1669.	6.5	8
169	Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. OncoTargets and Therapy, 2017, Volume 10, 5013-5030.	2.1	8
170	Systemic therapies in advanced hepatocellular carcinoma: How do older patients fare?. European Journal of Surgical Oncology, 2021, 47, 583-590.	1.0	8
171	Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer. British Journal of Cancer, 2008, 99, 577-583.	6.5	7
172	Sunitinib for advanced pancreatic neuroendocrine tumors. Expert Review of Anticancer Therapy, 2011, 11, 1817-1827.	2.5	7
173	Cetuximab Is Contraindicated in the Perioperative Treatment of Colorectal Liver Metastases. Journal of Clinical Oncology, 2015, 33, 2405-2406.	5.4	7
174	Adjuvant chemotherapy in biliary tract cancer: state of the art and future perspectives. Current Opinion in Oncology, 2020, 32, 364-369.	2.5	7
175	Druggable molecular alterations in bile duct cancer: potential and current therapeutic applications in clinical trials. Expert Opinion on Investigational Drugs, 2021, 30, 975-983.	4.0	7
176	Targeted Therapies for Perihilar Cholangiocarcinoma. Cancers, 2022, 14, 1789.	3.8	7
177	i and fatal neutropen and fatal neutropenic enterocolitis following adjuvant chemotherapy for breast cancer. Clinical Oncology, 1997, 9, 172-175.	1.4	6
178	Outcomes in patientsâ€‰â‰¥â€‰80Âyears with a diagnosis of a hepatopancreaticobiliary (HPB) malignancy. Medical Oncology, 2019, 36, 85.	2.7	6
179	Prospective study of change in liver function and fat in patients with colorectal liver metastases undergoing preoperative chemotherapy: protocol for the CLiFF Study. BMJ Open, 2020, 10, e027630.	2.1	6
180	Fibrolamellar carcinoma: Challenging the challenge. European Journal of Cancer, 2020, 137, 144-147.	2.9	6

#	Article	IF	Citations
181	The Influence of Patients' Age on the Outcome of Treatment for Pancreatic Ductal Adenocarcinoma. Pancreas, 2020, 49, 201-207.	1.1	6
182	Knowns and unknowns of bone metastases in patients with neuroendocrine neoplasms: A systematic review and meta-analysis. Cancer Treatment Reviews, 2021, 94, 102168.	8.0	6
183	Potential utility of liquid biopsies in the management of patients with biliary tract cancers: A review. World Journal of Gastrointestinal Oncology, 2021, 13, 1073-1085.	2.0	6
184	Pancreatic Enzyme Replacement Therapy for Patients Diagnosed With Pancreaticobiliary Cancer. Pancreas, 2021, 50, 1254-1259.	1.1	6
185	Everolimus-Induced Pneumonitis in Patients with Neuroendocrine Neoplasms: Real-World Study on Risk Factors and Outcomes. Oncologist, 2022, 27, 97-103.	4.1	6
186	Chemotherapy with or without selective internal radiation therapy for intrahepatic cholangiocarcinoma: Data from clinical trials. Hepatology, 2024, 79, 96-106.	8.1	6
187	BINGO: targeted therapy for advanced biliary-tract cancer. Lancet Oncology, The, 2014, 15, 778-780.	10.7	5
188	A protocol for a cluster-randomized controlled trial of a self-help psycho-education programme to reduce diagnosis delay in women with breast cancer symptoms in Indonesia. BMC Cancer, 2017, 17, 284.	2.6	5
189	Relative effectiveness of sunitinib versus everolimus in advanced pancreatic neuroendocrine tumors: an updated matching-adjusted indirect comparison. Journal of Comparative Effectiveness Research, 2018, 7, 947-958.	1.6	5
190	Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes . Cancer Management and Research, 2019, Volume 11, 7537-7556.	2.0	5
191	Outcomes in older patients with biliary tract cancer. European Journal of Surgical Oncology, 2021, 47, 569-575.	1.0	5
192	Ivosidenib: an investigational drug for the treatment of biliary tract cancers. Expert Opinion on Investigational Drugs, 2021, 30, 301-307.	4.0	5
193	Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANTâ€3 and RADIANTâ€4 trials. Cancer, 2021, 127, 2674-2682.	4.1	5
194	Is the Morphological Subtype of Extra-Pulmonary Neuroendocrine Carcinoma Clinically Relevant?. Cancers, 2021, 13, 4152.	3.8	5
195	hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. Cancers, 2021, 13, 5758.	3.8	5
196	Plasma Tie2 trajectories identify vascular response criteria for VEGF inhibitors across advanced biliary tract, colorectal and ovarian cancers. ESMO Open, 2022, 7, 100417.	4.3	5
197	Radical Resection in Entero-Pancreatic Neuroendocrine Tumors: Recurrence-Free Survival Rate and Definition of a Risk Score for Recurrence. Annals of Surgical Oncology, 2022, 29, 5568-5577.	1.9	5
198	The impact of the COVID-19 pandemic upon pancreatic cancer treatment (CONTACT Study): a UK national observational cohort study. British Journal of Cancer, 2023, 128, 1922-1932.	6.5	5

#	Article	IF	Citations
199	Adjuvant therapy for gastric cancer â€“ has the standard changed?. British Journal of Cancer, 2001, 84, 875-877.	6.5	4
200	Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer. British Journal of Cancer, 2004, 91, 1447-1452.	6.5	4
201	Targeted therapy for cholangiocarcinoma. The Lancet Gastroenterology and Hepatology, 2019, 4, 661-662.	8.2	4
202	HPB cancers in older patients | inclusion of older/senior patients in clinical trials. European Journal of Surgical Oncology, 2021, 47, 597-602.	1.0	4
203	The Potential Role of Liquid Biopsies in Advancing the Understanding of Neuroendocrine Neoplasms. Journal of Clinical Medicine, 2021, 10, 403.	2.5	4
204	Pneumoperitoneum Following Percutaneous Biliary Intervention: Not Necessarily a Cause for Alarm. CardioVascular and Interventional Radiology, 2008, 31, 439-443.	2.1	3
205	Erratum to â€œA systematic review of non-surgical treatments for pancreatic neuroendocrine tumoursâ€• [Cancer Treat Rev 40 (2014) 376â€“389]. Cancer Treatment Reviews, 2014, 40, 1037.	8.0	3
206	Characterization and Expression of Outer Membrane Protein A I Gene of Aeromonas veronii. The Journal of Northeast Agricultural University, 2015, 22, 15-21.	0.1	3
207	Everolimus in the Treatment of Neuroendocrine Tumors of the Respiratory and Gastroenteropancreatic Systems. Future Oncology, 2016, 12, 2561-2578.	2.4	3
208	Recruitment and Trial-Finding Appsâ€”Time for Rules of the Road. Journal of the National Cancer Institute, 2019, 111, 882-886.	6.3	3
209	Highlights from ASCO-GI 2021 from EORTC Gastrointestinal tract cancer group. British Journal of Cancer, 2021, 125, 911-919.	6.5	3
210	Should Patients with Resected Bile Duct Cancer Receive an Adjuvant Treatment?. The Journal of Oncopathology, 2014, 2, 57-68.	0.1	3
211	Prognostic factors for relapse in resected gastroenteropancreatic neuroendocrine neoplasms: A systematic review and meta-analysis. Cancer Treatment Reviews, 2021, 101, 102299.	8.0	3
212	Molecular Profiling of Well-Differentiated Neuroendocrine Tumours: The Role of ctDNA in Real-World Practice. Cancers, 2022, 14, 1017.	3.8	3
213	Clinical challenges associated with utility of neoadjuvant treatment in patients with pancreatic ductal adenocarcinoma. European Journal of Surgical Oncology, 2022, 48, 1198-1208.	1.0	3
214	Prospective Observational Study of Prevalence, Assessment and Treatment of Pancreatic Exocrine Insufficiency in Patients with Inoperable Pancreatic Malignancy (PANcreatic Cancer Dietary) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 137 Tc	3.8	3
215	Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies. European Journal of Cancer, 2024, 200, 113587.	2.9	3
216	Pharmacokinetics of a hematoregulatory peptide (SK&F107647) in healthy male volunteers and in patients with colorectal or pancreatic adenocarcinoma not amenable to standard therapy. Pharmaceutical Research, 2000, 17, 385-390.	3.5	2

#	Article	IF	Citations
217	Elderly patients diagnosed with hepatopancreatobiliary malignancies: A challenge beyond resection. Cancer, 2017, 123, 888-890.	4.1	2
218	Guidelines for Management of Urgent Symptoms in Patients with Cholangiocarcinoma and Biliary Stents or Catheters Using the Modified RAND/UCLA Delphi Process. Cancers, 2020, 12, 2375.	3.8	2
219	Second-line FOLFOX chemotherapy for advanced biliary tract cancer â€“ Authors' reply. Lancet Oncology, The, 2021, 22, e288-e289.	10.7	2
220	Looking Beyond Chemotherapy in Patients with Advanced, Well-differentiated, Pancreatic Neuroendocrine Tumors. The Journal of Oncopathology, 2014, 2, 15-25.	0.1	2
221	Use of the Rockwood Clinical Frailty Scale in patients with advanced hepatopancreaticobiliary malignancies. Expert Review of Anticancer Therapy, 2022, 22, 1009-1015.	2.5	2
222	Relevant Study: Patient and Clinician Perspectives on Clinically-Meaningful Outcomes in Advanced Pancreatic Cancer. Cancers, 2023, 15, 738.	3.8	2
223	Clinical and biological markers predictive of treatment response associated with metastatic pancreatic adenocarcinoma. British Journal of Cancer, 2023, 128, 1672-1680.	6.5	2
224	Variation in treatment of intrahepatic cholangiocarcinoma: a nationwide multicentre study. British Journal of Surgery, 2023, 110, 1673-1676.	0.3	2
225	Locoregional Treatment in Intrahepatic Cholangiocarcinoma: Which Treatment for Which Patient?. Cancers, 2023, 15, 4217.	3.8	2
226	Influence of cirrhosis on outcomes of patients with advanced intrahepatic cholangiocarcinoma receiving chemotherapy. British Journal of Cancer, 2023, 129, 1766-1772.	6.5	2
227	Patients With Pancreatic Cancer Participating in Clinical Trials. Pancreas, 2007, 34, 269-270.	1.1	1
228	Reply to the letter to the editor â€˜Second-line chemotherapy in advanced biliary cancer: the present now will later be pastâ€™ by Vivaldi et al.. Annals of Oncology, 2014, 25, 2444-2445.	1.3	1
229	Novel Treatments for Advanced Cholangiocarcinoma. , 2019, , 227-243.		1
230	FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?. ESMO Open, 2020, 5, e000633.	4.3	1
231	Reaching out beyond first-line treatments in advanced biliary tract cancers. Annals of Oncology, 2020, 31, 1099-1102.	1.3	1
232	Carboplatin-etoposide chemotherapy for patients with advanced extra-pulmonary (EP) poorly differentiated (PD) neuroendocrine carcinoma (NEC); outcomes from a European Neuroendocrine Tumour Society Centre of Excellence. Endocrine Abstracts, 0, , .	0.0	1
233	ESMO Congress 2021: highlights from the EORTC gastrointestinal tract cancer groupâ€™s perspective. ESMO Open, 2022, 7, 100392.	4.3	1
234	Highlights from the 2022 ASCO Gastrointestinal Cancer Symposium: an overview by the EORTC Gastrointestinal Tract Cancer Group. Clinical Colorectal Cancer, 2022, , .	2.4	1

#	Article	IF	Citations
235	The Management and Outcomes of Patients with Extra-Pulmonary Neuroendocrine Neoplasms and Brain Metastases. Current Oncology, 2022, 29, 5110-5125.	2.3	1
236	Third-Line Palliative Systemic Therapy for Advanced Biliary Tract Cancer: Multicentre Review of Patterns of Care and Outcomes. Cancers, 2023, 15, 3047.	3.8	1
237	Patients Undergoing Systemic Anti-Cancer Therapy Who Require Surgical Intervention: What Surgeons Need to Know. Cancers, 2023, 15, 3781.	3.8	1
238	Current Evidence for Immune Checkpoint Inhibition in Advanced Hepatocellular Carcinoma. Current Oncology, 2023, 30, 8665-8685.	2.3	1
239	Selection of Chemotherapy in Advanced Poorly Differentiated Extra-Pulmonary Neuroendocrine Carcinoma. Cancers, 2023, 15, 4951.	3.8	1
240	Prognosis Discussion and Referral to Community Palliative Care Services in Patients with Advanced Pancreatic Cancer Treated in a Tertiary Cancer Centre. Healthcare (Switzerland), 2023, 11, 2802.	2.1	1
241	Reply 1: Call for NICE to review urgently their guidance concerning first-line chemotherapy for metastatic colorectal cancer. British Journal of Cancer, 2003, 88, 1153-1154.	6.5	0
242	Irinotecan with Bolus and Infusional 5-flurouracil and Folinic Acid for Patients with Advanced or Metastatic Colorectal Cancer Previously Treated with 5-flurouracil: A Possible Alternative to Single-agent Irinotecan in a â€˜Real-lifeâ€™ Setting. Clinical Oncology, 2005, 17, 666.	1.4	0
243	Reply: Guesstimates are not good enough for determining what is happening in routine care. British Journal of Cancer, 2010, 103, 1887-1888.	6.5	0
244	Combination therapy of 177Lu and 90Y Dotatate for treatment of neuroendocrine cancer. Nuclear Medicine Communications, 2014, 35, 585-587.	1.1	0
245	The dark side of T1 non-appendiceal small bowel neuroendocrine tumors. Human Pathology, 2017, 66, 239-240.	2.3	0
246	Reply to Comment on â€œThe UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemicâ€• British Journal of Cancer, 2021, 124, 679-680.	6.5	0
247	Erratum to â€˜FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out?â€™. ESMO Open, 2021, 6, 100138.	4.3	0
248	Chemotherapy for Advanced Pancreatic Cancer: Available Drugs, Mechanisms and Toxicity. , 2021, , 681-696.		0
249	Clinical Management of Targeted Therapies in Neuroendocrine Tumours. , 2014, , 141-154.		0
250	Circulating Tumour Cells. , 2017, , 1-36.		0
251	Perspective on Immunotherapy Use in Biliary Tract Cancer. Cancer immunotherapy, 2022, , 207-218.	0.0	0
252	Hepatopancreaticobiliary Cancer in Older Adults with Frailty. , 2022, , 421-445.		0

#	Article	IF	Citations
253	Intrahepatic Cholangiocarcinoma With Extrahepatic Metastasis and High Tumor Mutation Burden: Case of Complete Pathological Response to Cisplatin/Gemcitabine/Pembrolizumab. JCO Precision Oncology, 2024, , .	3.1	0